These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 24316309)

  • 21. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
    Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
    Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling.
    Lee EK; Kim HJ; Lee KJ; Lee HJ; Lee JS; Kim DG; Hong SW; Yoon Y; Kim JS
    Int J Oncol; 2011 Feb; 38(2):325-33. PubMed ID: 21132267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
    Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
    Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
    Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
    Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aldo-keto reductase 1C3 is expressed in differentiated human epidermis, affects keratinocyte differentiation, and is upregulated in atopic dermatitis.
    Mantel A; Carpenter-Mendini AB; Vanbuskirk JB; De Benedetto A; Beck LA; Pentland AP
    J Invest Dermatol; 2012 Apr; 132(4):1103-10. PubMed ID: 22170488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of lipocalin 2 and its complex with matrix metalloproteinase-9 in oral cancer.
    Lin CW; Tseng SW; Yang SF; Ko CP; Lin CH; Wei LH; Chien MH; Hsieh YS
    Oral Dis; 2012 Nov; 18(8):734-40. PubMed ID: 22533572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paracrine-stimulated gene expression profile favors estradiol production in breast tumors.
    Amin SA; Huang CC; Reierstad S; Lin Z; Arbieva Z; Wiley E; Saborian H; Haynes B; Cotterill H; Dowsett M; Bulun SE
    Mol Cell Endocrinol; 2006 Jul; 253(1-2):44-55. PubMed ID: 16735089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.
    Fan L; Peng G; Hussain A; Fazli L; Guns E; Gleave M; Qi J
    J Biol Chem; 2015 Aug; 290(34):20865-20879. PubMed ID: 26160177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
    Matsunaga T; Hojo A; Yamane Y; Endo S; El-Kabbani O; Hara A
    Chem Biol Interact; 2013 Feb; 202(1-3):234-42. PubMed ID: 23165153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner.
    Mahadevan NR; Rodvold J; Almanza G; Pérez AF; Wheeler MC; Zanetti M
    BMC Cancer; 2011 Jun; 11():229. PubMed ID: 21649922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism.
    Mantel A; Carpenter-Mendini A; VanBuskirk J; Pentland AP
    Exp Dermatol; 2014 Aug; 23(8):573-8. PubMed ID: 24917395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells.
    Wang S; Yang Q; Fung KM; Lin HK
    Mol Cell Endocrinol; 2008 Jul; 289(1-2):60-6. PubMed ID: 18508192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
    Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
    Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
    Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
    Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer.
    Chung IH; Chen CY; Lin YH; Chi HC; Huang YH; Tai PJ; Liao CJ; Tsai CY; Lin SL; Wu MH; Chen CY; Lin KH
    Oncotarget; 2015 Jun; 6(17):15050-64. PubMed ID: 25940797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
    Azzarello JT; Lin HK; Gherezghiher A; Zakharov V; Yu Z; Kropp BP; Culkin DJ; Penning TM; Fung KM
    Int J Clin Exp Pathol; 2009 Nov; 3(2):147-55. PubMed ID: 20126582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implication of voltage-dependent anion channel 1 in uterine cervical cancer and its action on cervical cancer cells.
    Wu CH; Lin YW; Wu TF; Ko JL; Wang PH
    Oncotarget; 2016 Jan; 7(4):4210-25. PubMed ID: 26716410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
    Birtwistle J; Hayden RE; Khanim FL; Green RM; Pearce C; Davies NJ; Wake N; Schrewe H; Ride JP; Chipman JK; Bunce CM
    Mutat Res; 2009 Mar; 662(1-2):67-74. PubMed ID: 19162045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.
    Wang YP; Yu GR; Lee MJ; Lee SY; Chu IS; Leem SH; Kim DG
    Hepatology; 2013 Oct; 58(4):1349-61. PubMed ID: 23696034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.